Summary

Eligibility
for people ages up to 29 years (full criteria)
Location
at Oakland, California and other locations
Dates
study started

Description

Summary

This phase III trial studies how well combination chemotherapy and surgery work in treating young patients with Wilms tumor. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Giving combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving it after surgery may kill any tumor cells that remain after surgery.

Official Title

Treatment for Patients With Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor

Details

Keywords

Adult Kidney Wilms Tumor, Beckwith-Wiedemann Syndrome, Childhood Kidney Wilms Tumor, Diffuse Hyperplastic Perilobar Nephroblastomatosis, Rhabdoid Tumor of the Kidney, Stage I Kidney Wilms Tumor, Stage II Kidney Wilms Tumor, Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor, Stage V Kidney Wilms Tumor, Neoplasms, Wilms Tumor, Rhabdoid Tumor, Kidney Neoplasms, Dactinomycin, Cactinomycin, Doxorubicin, Liposomal doxorubicin, Vincristine, Doxorubicin Hydrochloride, Radiation Therapy, Vincristine Sulfate, Bilateral Wilms Tumors, DHPLN

Eligibility

Locations

Details

Status
in progress, not accepting new patients
Start Date
Sponsor
Children's Oncology Group
Links
Data Available: Select individual patient-level data from this trial can be requested from the NCTN/NCORP Data Archive
ID
NCT00945009
Phase
Phase 3 research study
Study Type
Interventional
Participants
About 249 people participating
Last Updated